Salicylic acid

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the text.

Uses and Indications

This drug is indicated for the removal of common and plantar warts. Common warts are characterized by their rough, “cauliflower-like” surface appearance, while plantar warts are specifically located on the bottom of the foot, presenting with tenderness and an interruption of the footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. It is recommended to soak the wart in warm water for approximately 5 minutes, followed by drying the area completely.

Using the provided applicator, which may be a brush or cotton swab, one drop of the medication should be applied at a time to ensure complete coverage of each wart. It is essential to allow the medication to fully absorb and dry after application.

This procedure may be repeated once or twice daily as necessary, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

The product is contraindicated for use on irritated skin or any area that is infected or reddened. It should not be applied to moles, birthmarks, warts with hair growing from them, or warts located on the face or mucous membranes.

Use of the product is also contraindicated in patients with diabetes or poor blood circulation due to the risk of exacerbating these conditions. Discontinue use if discomfort persists.

Additionally, avoid contact with eyes; in case of contact, flush the eye with water for 15 minutes. Inhalation of vapors should be avoided.

Keep the product out of reach of children. If ingested, seek medical assistance or contact a Poison Control Center immediately.

Warnings and Precautions

For external use only. It is imperative to keep the product away from fire and flame, and it should only be applied to the affected area to ensure safety and efficacy.

In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Patients are advised to discontinue use and consult a healthcare professional if discomfort persists. Special caution is warranted for individuals with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

Side Effects

Patients using this product should be aware that it is intended for external use only and must be applied solely to the affected area. It is crucial to keep the product away from fire and flame to prevent any potential hazards.

In clinical practice, patients are advised to discontinue use if discomfort persists. Special caution is warranted for individuals with diabetes or poor blood circulation, as these conditions may exacerbate adverse reactions.

Additionally, it is important to keep this product out of reach of children. In the event of accidental ingestion, patients should seek medical assistance or contact a Poison Control Center immediately.

Drug Interactions

There are no reported drug interactions associated with the use of this medication. Additionally, no interactions with laboratory tests have been identified. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Aijieyo Wart Remover. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

There is no information available regarding the use of AIJIEYO WART REMOVER during pregnancy, including safety concerns, dosage modifications, or any special precautions that should be taken. Healthcare professionals should exercise caution when considering the use of this product in pregnant patients due to the lack of data on potential risks or fetal impacts. Women of childbearing potential should be advised to consult their healthcare provider for guidance before using this product during pregnancy.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or any considerations related to lactation. Therefore, healthcare professionals should exercise caution when prescribing this medication to lactating mothers, as the effects on breastfed infants are not well characterized. It is advisable to monitor breastfed infants for any potential adverse effects if the medication is administered to nursing mothers.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdosage, immediate medical assistance is crucial. If the substance is ingested, healthcare professionals should advise patients or caregivers to seek medical help or contact a Poison Control Center without delay.

Prompt intervention is essential to mitigate potential adverse effects associated with overdosage. Symptoms may vary depending on the specific substance involved, and healthcare providers should be prepared to assess and manage these symptoms accordingly.

Management procedures may include supportive care and symptomatic treatment, tailored to the individual patient's needs. Continuous monitoring and evaluation are recommended to ensure patient safety and effective resolution of any complications arising from the overdosage.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available for SPL code 90375-7.

Patient Counseling

Healthcare providers should advise patients to store this product out of the reach of children to prevent accidental ingestion. Patients should be informed that if discomfort persists after use, they should discontinue use immediately.

For patients with diabetes or poor blood circulation, it is essential to instruct them to stop using the product and seek medical advice. In the event of accidental swallowing, patients must be directed to seek medical help or contact a Poison Control Center without delay.

Providers should emphasize the importance of avoiding contact with the eyes. If the product inadvertently gets into the eye, patients should be instructed to flush the eye with water for at least 15 minutes. Additionally, patients should be cautioned against inhaling vapors from the product.

It is important to remind patients to cap the bottle tightly after use and to store the product out of direct sunlight, at room temperature, and away from heat sources to maintain its efficacy.

Storage and Handling

The product is supplied in a container that must be capped tightly after each use to maintain its integrity. It should be stored out of direct sunlight and at room temperature, ensuring it is kept away from heat sources. Additionally, it is essential to keep the product out of reach of children to ensure safety during storage.

Additional Clinical Information

The medication is administered topically, with the recommended frequency being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Aijieyo Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)